Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination

ABSTRACT We investigated the antimicrobial activity of four polymyxin B components, B1, B2, B3, and isoleucine (Ile)-B1, individually and in combination. B3 was the most active agent against all organisms tested except Acinetobacter baumannii, for which Ile-B1 was most active. One combination met the criteria for synergy, B3 plus Ile-B1. No combinations exhibited antagonism. The dominant components of polymyxin B products (B1 and B2) were associated with the lowest probability of improved antibacterial activity when combined.

[1]  Ronald N. Jones,et al.  Polymyxins: wisdom does not always come with age. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  C. Landersdorfer,et al.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Humphries,et al.  Colistin MIC Variability by Method for Contemporary Clinical Isolates of Multidrug-Resistant Gram-Negative Bacilli , 2013, Journal of Clinical Microbiology.

[4]  Ronald N. Jones,et al.  Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. , 2012, Diagnostic microbiology and infectious disease.

[5]  V. Tam,et al.  Pharmacokinetics and Renal Disposition of Polymyxin B in an Animal Model , 2012, Antimicrobial Agents and Chemotherapy.

[6]  V. Tam,et al.  In Vitro Potency of Various Polymyxin B Components , 2011, Antimicrobial Agents and Chemotherapy.

[7]  V. Tam,et al.  Variability of polymyxin B major components in commercial formulations. , 2010, International journal of antimicrobial agents.

[8]  J. Li,et al.  Pharmacokinetics of intravenous polymyxin B in critically ill patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Ronald N. Jones,et al.  In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. , 2008, Diagnostic microbiology and infectious disease.

[10]  A. Van Schepdael,et al.  Isolation and structural characterization of polymyxin B components. , 2001, Journal of chromatography. A.

[11]  E. Roets,et al.  Liquid chromatography of polymyxin B sulphate. , 2000, Journal of chromatography. A.

[12]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[13]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .